【摘要】 角膜移植手术是对角膜病治疗的主要手段。虽然角膜因其无血管,无淋巴管的特性,属于相对免疫赦免区,但仍不能避免免疫排斥这一器官移植所面对的困扰。尤其是一些大植片,片中心或有新生血管形成的角膜病患者,仍属于高危移植类型。很多患者因为排斥而不得不更换植片,但多次角膜移植又会引发更严重的排斥,而且供体来源稀缺,不能满足患者的需求。所以,各国的研究者都很重视对药物防治术后免疫排斥反应的研究。目前,很多临床研究证明,抗排斥的一线用药如糖皮质激素,环孢素A等,还不能达到满意的疗效,同时还有许多副作用。因此,探讨新型的免疫抑制剂等新抗排斥药物,联合用药的方法已成为眼科角膜病医生的重要研究课题。更多还原

【Abstract】 Corneal transplantation has been considered a primary method for treatment of keratopathy.Corneal transplantation would bring immunological rejection although cornea belongs to an immune-privileged tissue owing to no vessels and lymphatic vessels.Immunological rejection is highly likely to occur in keratopathy patients who undergo large sizes of corneal transplantation or present with newly formed vessels in the center of implant.Many patients have to replace other implants because of immunological rejection.But severer immunological rejection caused by several corneal transplantations as well as rare donor source can not satisfy patients’ requirement.Therefore,much attention has been paid to studies regarding drugs for immunologic protection following surgery.There have been many clinical studies confirming that the principle drugs against immunologic rejection,such as glucocorticoid and ciclosporin A,can not acquire satisfactory curative effects and concomitantly bring many adverse reactions.For this reason,many new immunosuppressive agents should be investigated.The method of drug combination has become an important research project for keratopathy physicians.更多还原